- Home
- RMBI vs SLGL Comparison
RMBI vs SLGL Comparison
Compare RMBI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMBI | SLGL |
|---|---|---|
| Founded | 1887 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 117.8M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMBI | SLGL |
|---|---|---|
| Price | $13.98 | $43.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 24.4K | 15.0K |
| Earning Date | 01-22-2026 | 11-20-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ 21.88 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $44,970,551.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | 6.42 | ★ 62.04 |
| 52 Week Low | $11.37 | $4.02 |
| 52 Week High | $15.24 | $52.26 |
Technical Indicators
Market Signals| Indicator | RMBI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 59.34 |
| Support Level | $14.01 | $38.91 |
| Resistance Level | $14.48 | $43.12 |
| Average True Range (ATR) | 0.32 | 3.23 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 52.22 | 81.72 |
Price Performance
Historical ComparisonAbout RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.